Naohito Isoyama1, Abdul Rashid Qureshi2, Carla Maria Avesani3, Bengt Lindholm2, Peter Bàràny2, Olof Heimbürger2, Tommy Cederholm4, Peter Stenvinkel2, Juan Jesús Carrero5. 1. Divisions of Renal Medicine and Baxter Novum, and Department of Urology, Yamaguchi University, Yamaguchi, Japan; 2. Divisions of Renal Medicine and Baxter Novum, and. 3. Department of Applied Nutrition, Nutrition Institute, Rio de Janeiro State University, Rio de Janeiro, Brazil; and. 4. Division of Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden. 5. Divisions of Renal Medicine and Baxter Novum, and Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden; juan.jesus.carrero@ki.se.
Abstract
BACKGROUND AND OBJECTIVES: Reduced muscle mass and strength are prevalent conditions in dialysis patients. However, muscle strength and muscle mass are not congruent; muscle strength can diminish even though muscle mass is maintained or increased. This study addresses phenotype and mortality associations of these muscle dysfunction entities alone or in combination (i.e., concurrent loss of muscle mass and strength/mobility, here defined as sarcopenia). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study included 330 incident dialysis patients (203 men, mean age 53±13 years, and mean GFR 7±2 ml/min per 1.73 m(2)) recruited between 1994 and 2010 and followed prospectively for up to 5 years. Low muscle mass (by dual-energy x-ray absorptiometry appendicular mass index) and low muscle strength (by handgrip) were defined against young reference populations according to the European Working Group on Sarcopenia in Older People. RESULTS: Whereas 20% of patients had sarcopenia, low muscle mass and low muscle strength alone were observed in a further 24% and 15% of patients, respectively. Old age, comorbidities, protein-energy wasting, physical inactivity, low albumin, and inflammation associated with low muscle strength, but not with low muscle mass (multivariate ANOVA interactions). During follow-up, 95 patients (29%) died and both conditions associated with mortality as separate entities. When combined, individuals with low muscle mass alone were not at increased risk of mortality (adjusted hazard ratio [HR], 1.23; 95% confidence interval [95% CI], 0.56 to 2.67). Individuals with low muscle strength were at increased risk, irrespective of their muscle stores being appropriate (HR, 1.98; 95% CI, 1.01 to 3.87) or low (HR, 1.93; 95% CI, 1.01 to 3.71). CONCLUSIONS: Low muscle strength was more strongly associated with aging, protein-energy wasting, physical inactivity, inflammation, and mortality than low muscle mass. Assessment of muscle functionality may provide additional diagnostic and prognostic information to muscle-mass evaluation.
BACKGROUND AND OBJECTIVES: Reduced muscle mass and strength are prevalent conditions in dialysis patients. However, muscle strength and muscle mass are not congruent; muscle strength can diminish even though muscle mass is maintained or increased. This study addresses phenotype and mortality associations of these muscle dysfunction entities alone or in combination (i.e., concurrent loss of muscle mass and strength/mobility, here defined as sarcopenia). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study included 330 incident dialysis patients (203 men, mean age 53±13 years, and mean GFR 7±2 ml/min per 1.73 m(2)) recruited between 1994 and 2010 and followed prospectively for up to 5 years. Low muscle mass (by dual-energy x-ray absorptiometry appendicular mass index) and low muscle strength (by handgrip) were defined against young reference populations according to the European Working Group on Sarcopenia in Older People. RESULTS: Whereas 20% of patients had sarcopenia, low muscle mass and low muscle strength alone were observed in a further 24% and 15% of patients, respectively. Old age, comorbidities, protein-energy wasting, physical inactivity, low albumin, and inflammation associated with low muscle strength, but not with low muscle mass (multivariate ANOVA interactions). During follow-up, 95 patients (29%) died and both conditions associated with mortality as separate entities. When combined, individuals with low muscle mass alone were not at increased risk of mortality (adjusted hazard ratio [HR], 1.23; 95% confidence interval [95% CI], 0.56 to 2.67). Individuals with low muscle strength were at increased risk, irrespective of their muscle stores being appropriate (HR, 1.98; 95% CI, 1.01 to 3.87) or low (HR, 1.93; 95% CI, 1.01 to 3.71). CONCLUSIONS: Low muscle strength was more strongly associated with aging, protein-energy wasting, physical inactivity, inflammation, and mortality than low muscle mass. Assessment of muscle functionality may provide additional diagnostic and prognostic information to muscle-mass evaluation.
Authors: B H Goodpaster; C L Carlson; M Visser; D E Kelley; A Scherzinger; T B Harris; E Stamm; A B Newman Journal: J Appl Physiol (1985) Date: 2001-06
Authors: A R Qureshi; A Alvestrand; A Danielsson; J C Divino-Filho; A Gutierrez; B Lindholm; J Bergström Journal: Kidney Int Date: 1998-03 Impact factor: 10.612
Authors: Constantijn J A M Konings; Jeroen P Kooman; Marc Schonck; Bernardus van Kreel; Guido A K Heidendal; Emile C Cheriex; Frank M van der Sande; Karel M L Leunissen Journal: Perit Dial Int Date: 2003 Mar-Apr Impact factor: 1.756
Authors: Jorge L Gamboa; Baback Roshanravan; Theodore Towse; Chad A Keller; Aaron M Falck; Chang Yu; Walter R Frontera; Nancy J Brown; T Alp Ikizler Journal: Clin J Am Soc Nephrol Date: 2020-06-26 Impact factor: 8.237
Authors: Piyawan Kittiskulnam; Glenn M Chertow; Juan J Carrero; Cynthia Delgado; George A Kaysen; Kirsten L Johansen Journal: Kidney Int Date: 2017-03-17 Impact factor: 10.612